During this session we will quickly cover the basics of the inflation reduction act and then spend some time considering the implications of this major policy milestone on different types of medications. We’ll also review the first set of products that have been selected for Government negotiation and how / why that’s going to shake up the landscape.

The Molekule team will provide an overview of recent trends impacting market access strategies, discuss a few case studies focused on competitive intelligence and its role in shaping market access strategies, and recommendations on best practices.

1. Artificial intelligence (AI) in Pharma:
• AI technologies to enhance the lifecycle of drug development from discovery to distribution could potentially lead to greater efficiency, lower costs, and better outcomes in the Pharma and Biotech industries. Is the use of AI fuelling increased competition through a higher need for differentiation?
2. AI for CI:
• In CI, AI has the potential to increase the speed of insights, however, analysis and accuracy of insights is still evolving. How much can we trust AI and what should we be mindful of when integrating AI for CI?
3. M&A trends in Pharma:
• M&A trends in the pharma industry can fluctuate based on a myriad of factors including market dynamics and macroeconomic factors. Perhaps a bit early to tell, what is the expected impact of IRA (Inflation reduction act) on driving innovation for US pharma? How much differentiation is needed to drive M&A?

Witness firsthand how this evolution empowers CI efforts with newfound efficiency and transparency. Through live notifications, the platform empowers teams to stay always-in-the-know about trials’ evolving events and protocol changes. Experience the shift that has redefined how Takeda’s CI operates, enabling users to not only manage trials, but thrive in the ever-evolving landscape of pharmaceutical competition.

Expectations of what the competitive intelligence function should be able to do will inevitably increase. In this talk we will discuss how those expectations create opportunities and how you can be ready to make the most of those opportunities.

In this session, you will learn how these strategic insights can be generated systematically and used to discover emerging opportunities and risks, anticipate how other players may or may not respond to them, and create more robust strategies for navigating the complex and dynamic competitive landscape as it evolves.

Rather than a competitive race with other divisions that often leads to sending mixed signals to senior leaders, when functional teams collaborate across the organization, they are able to drive more impact from their competitive intelligence efforts. One of Organon’s key values is “We All Rise Together”, this cross-functional team will share their journey in overcoming internal silos to create a winning team and magnify the value and impact of competitive intelligence across the organization.

The far-reaching Inflation Reduction Act curbs profits on high-spend drugs, while the anti-trust FTC is apparently willing to try and block M&A deals that may encourage dubious pricing practices. Meanwhile, regulators are less predictable in the face of new modalities.

With this as the backdrop to the current reality for biopharma companies and their investors, let’s take a step back. Based on Evaluate’s annual World Preview report, this presentation will focus not only on the forces of uncertainty, but will also look at the future, featuring our latest forecast data out to 2028. We’ll highlight:
– The forecasted top 10 companies and products in 2028
– The most highly valued R&D projects and pipeline assets
– What’s driving the changing focus of big pharma toward widespread diseases
– How the dealmaking landscape is changing to address patent cliffs, changing regulations and an uncertain legislative environment.

In this session, see how a generative AI application optimized for pharma CI answers direct questions about industry topics, company strategies, and cutting-edge research initiatives, deriving its answers from (and citing) credible research sources, ensuring that researchers can rely on and validate the AI work product.

The laborious task of creating concise, yet accurate news summaries is a perfect pairing for proprietary machine learning with mainstream generative AI. Don’t miss this session if you think CI should be conversing with your organization’s digital transformation stakeholders.

However, CI companies need to keep pace with client cost pressures, the monitoring of complex TAs, and the challenges of achieving robust primary intelligence. To achieve this, they must continue to innovate and differentiate themselves, going beyond delivering competitive insights, by creating value across the product lifecycle through the delivery of science-driven strategic projects.

In this talk we will provide some guidance and perspectives.

It involves the gathering, analysis, and interpretation of information about competitors, market trends, and customer behavior. To streamline and enhance the CI process, the integration of ChatGPT API onto the SPRING Platform presents an innovative solution. This cutting-edge integration harnesses the power of artificial intelligence to provide users with an array of benefits, ultimately enabling you to make more informed strategic decisions.

Combining SPRING Platform streamlined workflows and personalized insights, from customized Primary and secondary intelligence, with the power of ChatGPT API, competitive intelligence becomes more efficient, accurate, and valuable than ever before, enabling businesses to thrive in today’s dynamic market environment.

Join us for an immersive session filled with valuable insights and actionable strategies that will take your Competitive Intelligence efforts to new heights. Secure your spot now for the next PharmaCI conference.

The drug developers who most effectively operationalize their clinical trial diversity plans will not only gain a whole new knowledge base, but will be in the best position to tap into the markets of the future in our increasingly diverse America. Even when key business questions don’t take this into account, our role as CI professionals is to illuminate blind spots for our stakeholders and deliver the insights they need now to gain and maintain the competitive advantage in this context. In this presentation, we will explain from experience how to integrate racial and gender diversity considerations into clinical intelligence deliverables. We will discuss the benefits and challenges of incorporating this new way of thinking, and share a couple of examples of key business decisions these types of novel insights can inform.

In this session we will discuss AstraZeneca’s global department Information Practice (IP) capabilities that automate our Oncology pipeline clinical needs. Our unique AI -based approach towards Oncology clinical trial designs leverages an custom built innovative information pipeline combining both AI and human expertise in the most efficient way across targeted literature searches towards complex tumor mapping AND AI driven biomarker inclusion and exclusion criteria.

We will examine real-world use cases where AI and automation have proven successful in CI, enabling CI teams to allocate more time to higher-level activities.

Key Topics:
• Using machine learning to help sift through the tsunami of daily information flow.
o Case Study: Training an AI to alert you to the important new information in clinicaltrials.gov
• Using ChatGPT or similar AIs to add natural language processing to your system. What you should and should not expect.
• Why AI is unlikely to replace CI experts – the tool vs the solution.

Conclusion:
AI offers significant potential for reducing the burden of CI’s workload. By distinguishing between the hype and reality, we can harness these technologies to empower CI professionals, enabling them to focus on higher-level activities, maximize launch revenue, and improve response times to competitive moves. Embracing AI and automation in CI practices can revolutionize the way we manage and extract value from vast amounts of information in today’s competitive landscape.

AI is revolutionising supply chains across industries, and clinical trials are no exception. Join us to hear how AI will enable faster, safer, and significantly less expensive clinical trials. Discover what the future may lie ahead for clinical trials in silico, learn what is an N=1 trial and how this paves the way for the future of personalised medicine.

While there are automated tools to collect and source news feeds- analysis, curation and distribution of competitive insights still remain a huge challenge. This session’s goal is to share how digital technologies can help create a single, unified productivity and workflow platform to collect, curate, and deliver intel/alerts to enable better and faster decision-making across the organization.

To implement this into our daily business activity will demand three critical changes to our business practices. Join us for a look into the results of these next generation probability of success predictions and what happens on the other side of making these three critical changes to our business processes.

1. Advance your understanding of core regulatory routes, timelines and strategies
2. Understand core Gx/biosimilar product development and entry strategies
3. Learn from & set up a best-in-industry Gx/biosimilar regulatory intelligence (RI) and CI tracking program
The presentation will be supported by thought provoking real-world case studies to stress differences between theory vs actual approaches

Developing, launching and growing blockbuster brands require a well-defined strategic decision making process.

In this presentation, we will share our proven 3 step process needed to identify your key competitors, assess several credible scenarios, determine risks and opportunities, identify the key success factors, and create an action plan to execute within your winning strategy.

The presentation incorporates learnings from leading the CI functions at Roche and Novartis, supporting the majority of Big Pharma companies CI efforts, the latest management thinking from Harvard Business School, and years of cross-functional experience within Pharma and at Atacana.

We look forward to seeing you there!